FCGR2A and infection: Protective immunity against all four DENV serotypes is a requirement for a safe and effective vaccine because, in a process known as Antibody Dependent Enhancement (ADE), low affinity or low concentration antibodies are believed to increase infection rates by binding virus particles and targeting them to cells expressing the Fcγ receptor (FcγR) [28], [29], [30].